Rapid identification of daratumumab interference with M-protein detection using MALDI-TOF mass spectrometry: a case study involving renal light chain amyloidosis
Open Access
- 16 July 2025
- journal article
- case report
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 46, e00493
Abstract
No abstract availableKeywords
Funding Information
- Shenzhen Science and Technology Innovation Program
- Peking University Shenzhen Hospital
- Shenzhen Science and Technology Innovation Commission (JCYJ20240813120000002)
This publication has 11 references indexed in Scilit:
- The Therapeutic Monoclonal Antibody Pemivibart Causes Persistent Interference in Immunofixation ElectrophoresisThe Journal of Applied Laboratory Medicine, 2025
- New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-19JAMA, 2024
- Systemic Light Chain AmyloidosisNew England Journal of Medicine, 2024
- Belimumab Is an IgG Lambda Therapeutic Monoclonal Antibody with the Potential to Cause Misdiagnosis of a Monoclonal GammopathyClinical Chemistry, 2024
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 updateAnnals of the Rheumatic Diseases, 2023
- The emerging therapeutic landscape of relapsed/refractory multiple myelomaAnnals of Hematology, 2022
- Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working groupAmyloid, 2022
- Daratumumab: A review of current indications and future directionsSeminars in Oncology, 2022
- Daratumumab-Based Treatment for Immunoglobulin Light-Chain AmyloidosisNew England Journal of Medicine, 2021
- Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDABlood, 2020